on NFL BIOSCIENCES (EPA:ALNFL)
NFL Biosciences Successfully Raises €3 Million in Capital Increase
On May 23, 2025, NFL Biosciences announced the successful completion of a capital increase, capped at €3 million. The biopharmaceutical company secured €2.4 million from qualified international and French investors and an additional €0.6 million via retail investors on the PrimaryBid platform. The offering, oversubscribed at €3.5 million, was set at a discounted subscription price to the recent average trading price.
The newly raised funds will support NFL Biosciences' Phase 3 trial of its smoking cessation treatment, NFL-101. Drawing from a cash reserve of €1.9 million and anticipated non-dilutive financing, the company is poised to fully fund this stage estimated at €4.5 million. Settlement of shares will occur on May 27, 2025, in line with the Euronext Growth Paris market debut.
With this financing round, NFL Biosciences increases its share capital to €380,167.26, issuing 2.5 million new shares, representing a significant stakeholder shift. Both institutional and retail investor participation underscores the confidence in NFL's vision and innovative addiction treatments.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NFL BIOSCIENCES news